Redhill Biopharma Ltd. (RDHL) — SEC Filings
Redhill Biopharma Ltd. (RDHL) — 50 SEC filings. Latest: EFFECT (May 6, 2026). Includes 47 6-K, 1 EFFECT, 1 20-F.
View Redhill Biopharma Ltd. on SEC EDGAR
Overview
Redhill Biopharma Ltd. (RDHL) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Apr 30, 2026: RedHill Biopharma Ltd. filed a Form 6-K on April 30, 2026. This report is for a foreign issuer and provides information as of the period ending April 30, 2026. The filing includes a 6-K document and a graphic image file.
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 14 bullish, 2 bearish, 34 neutral. The dominant filing sentiment for Redhill Biopharma Ltd. is neutral.
Filing Type Overview
Redhill Biopharma Ltd. (RDHL) has filed 1 EFFECT, 47 6-K, 1 20-F, 1 SC 13G/A with the SEC between Oct 2024 to May 2026.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of RDHL's 41 recent filings, 0 were flagged as high-risk, 28 as medium-risk, and 13 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Top Tags
drug-development (6) · foreign-private-issuer (5) · legal-win (4) · pharmaceutical (4) · clinical-trial (4) · corporate-governance (4) · shareholder-meeting (4) · regulatory-filing (3) · financing (3) · litigation (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Standby Equity Purchase Facility | $10 million | Maximum potential capital infusion over 36 months |
| Agreement Duration | 36 months | Period over which RedHill Biopharma can sell shares |
| Compliance Deadline | April 20, 2026 | The date by which RedHill Biopharma must meet Nasdaq's minimum bid price requirement. |
| Middle East Deal Value | $1.8M+ | Represents the upfront value of the new distribution agreement for Talicia®. |
| Summary Judgment | $10 million | Amount awarded to RedHill Biopharma after appeal. |
| Reporting Period | Q2 2025 | Financial and business updates are for this period. |
| Legal Costs Awarded | $1.8M | Additional amount awarded by the New York Supreme Court. |
| Prior Summary Judgment | $8.25M | Amount won in a previous legal decision. |
| Total Awarded | $10.05M | Combined amount from the summary judgment and legal costs. |
| Licensing Payments | $1.1M | Received for Talicia® |
| Equity Line | $10.0M | Maximum amount RedHill Biopharma can sell to Alumni Capital LP |
| Summary Judgment Award | $8.25 million | Amount awarded to RedHill Biopharma in legal victory. |
| Compliance Period | 180 days | Timeframe to regain minimum stockholders' equity |
| Potential Market Disruption | $100B | The press release suggests opaganib could disrupt a market of this size. |
| Total Assets | $414.8B | Represents the company's total assets as of December 31, 2024. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Redhill Biopharma Ltd. (RDHL)?
Redhill Biopharma Ltd. has 50 recent SEC filings from Oct 2024 to May 2026, including 47 6-K, 1 EFFECT, 1 20-F. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of RDHL filings?
Across 50 filings, the sentiment breakdown is: 14 bullish, 2 bearish, 34 neutral. The dominant sentiment is neutral.
Where can I find Redhill Biopharma Ltd. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Redhill Biopharma Ltd. (RDHL) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Redhill Biopharma Ltd.?
Financial highlights for Redhill Biopharma Ltd. are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.
What is the investment thesis for RDHL?
Investment thesis data for RDHL will be available once enriched filings are processed.
Who are the key executives at Redhill Biopharma Ltd.?
Executive information for Redhill Biopharma Ltd. is extracted from SEC filings as they are enriched with AI analysis.
What are the main risk factors for Redhill Biopharma Ltd. stock?
Of RDHL's 41 assessed filings, 0 were flagged high-risk, 28 medium-risk, and 13 low-risk.
What are recent predictions and forward guidance from Redhill Biopharma Ltd.?
Forward guidance and predictions for Redhill Biopharma Ltd. are extracted from SEC filings as they are enriched.